The pattern is now familiar enough to predict. An employer adds GLP-1 coverage, uptake is far higher than the actuaries assumed, the line item becomes one of the largest in the pharmacy budget, and at the next plan year the benefit is narrowed, capped, or removed.
State Medicaid programmes have run the same sequence, on a larger scale and with less warning.
Why this keeps happening
The arithmetic that surprised everyone: eligibility for these drugs is not a niche. A very large share of any adult population meets the clinical criteria, uptake has been high, and unlike most chronic medications there is no cheap generic to fall back on.
Plans that budgeted for a specialty medication found themselves paying for something closer to a population-level intervention.
The common responses, roughly in order of how often I see them:
- BMI thresholds raised, so people who qualified last year no longer do
- Step therapy added, requiring documented failure of another approach first
- Duration caps, commonly twelve or twenty-four months, which is a strange thing to apply to a chronic condition
- Programme participation required, tying the drug to a lifestyle vendor
- Outright removal of the anti-obesity category
A duration cap on treatment for a chronic relapsing disease is not a clinical policy. It is a budget expressed in clinical language.
What a lapse actually does
This is the part that gets treated as an administrative inconvenience and is not one.
Withdrawal data across this class is consistent: appetite returns within days to weeks, and most of the lost weight follows over the subsequent year, along with the cardiometabolic improvements that came with it. A person interrupted at month fourteen does not resume at month fourteen when coverage returns — they restart, re-titrate, and repeat a good deal of the difficulty.
What to do, in order
- Read the actual formulary at open enrollment. Not the summary. The drug list, with tiers and restrictions. Employers must provide it.
- Ask the benefits team directly, in writing, whether anti-obesity medications are covered next plan year and under what criteria. The pharmacy help line is frequently wrong.
- Check whether another indication applies to you. Cardiovascular disease, sleep apnea, kidney disease and liver disease each have approved GLP-1 indications that sit outside a weight-loss exclusion.
- Get the documentation together now. A dated record of dose, weight, blood pressure and comorbidity improvement is the strongest material in any appeal or exception request, and it cannot be created retrospectively. If you are not keeping one, Zenday will produce something exportable — start it this month rather than the month you need it.
- Price the alternatives before you need them. Manufacturer cash channels, a covered alternative agent, a lower dose. Knowing the fallback in October is worth a great deal in January.
The argument employers are actually making
It is worth understanding rather than dismissing, because it is not stupid.
Employees change jobs every few years. The cardiovascular and metabolic savings from treating obesity accrue over decades. An employer paying for treatment today largely funds a benefit that a different employer, or Medicare, will eventually collect.
That is a real structural problem, and it is not solved by criticising benefits managers. It is solved by not funding chronic disease treatment through employment — which is a much larger argument than this article.
In the meantime, the practical position is uncomfortable and simple: treat your coverage as temporary, and know your next move before you need it.